Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 601-605

  Bass, Johnnie K ^a,b   Huang, Jie ^a   Onar Thomas, Arzu ^a   Chang, Kay W ^c   Bhagat, Shaum P ^a,b   Chintagumpala, Murali ^d   Bartels, Ute ^e   Gururangan, Sridharan ^f   Hassall, Tim ^g   Heath, John A ^h   Mccowage, Geoffrey ⁱ   Cohn, Richard J ^j   Fisher, Michael J ^k   Robinson, Giles ^a   Broniscer, Alberto ^a   Gajjar, Amar ^a   Gurney, James G ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c STANFORD UNIVERSITY   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

^h ROYAL CHILDREN'S HOSPITAL   (Australia)

ⁱ CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^j SYDNEY CHILDREN'S HOSPITAL   (Australia)

^k CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

more..

Author keywords

Cisplatin; Hearing loss; Late effects; Medulloblastoma; Ototoxicity

Indexed keywords

AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUDIOGRAPHY; AUDIOLOGY; AUDIOMETRY; BONE MARROW RESCUE; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CRANIOSPINAL IRRADIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEARING AID; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; OTOTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SIOP OTOTOXICITY GRADING SCALE; STEM CELL TRANSPLANTATION; TREATMENT DURATION; YOUNG ADULT;

CISPLATIN; HEARING LOSS; LATE EFFECTS; MEDULLOBLASTOMA; OTOTOXICITY;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHINA; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS; HUMANS; INTERNATIONAL AGENCIES; MALE; MEDULLOBLASTOMA; PROGNOSIS; YOUNG ADULT;

EID: 84893498559     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24830     Document Type: Article

References (28)

1. Brock PR, Knight KR, Freyer DR, et al. Platinum-based ototoxicity in children: A consensus review on mechanisms, predisposition and protection including a new SIOP Boston Ototoxicity Scale. J Clin Oncol 2012; 30:2408-2417.
2. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991; 19:295-300.
3. Blakely BW, Myers SF. Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol Head Neck Surg 1993; 109:385-391.
4. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 2004; 40:2445-2451.
5. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23:8588-8596.
6. Stelmachowicz PG, Pittman AL, Hoover BM, et al. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004; 130:556-562.
7. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: Prevalence, educational performance, and functional status. Ear Hear 1998; 19:339-354.
8. Davis JM, Elfenbein J, Schum R, Bentler RA. Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord 1986; 51:53-62.
9. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics 1998; 102:1161-1171.
10. Yoshinaga-Itano C. Benefits of early intervention for children with hearing loss. Otolaryngol Clin North Am 1999; 32:1089-1102.
11. Downs MP, Yoshinaga-Itano C. The efficacy of early identification and intervention for children with hearing impairment. Pediatr Clin North Am 1999; 46:79-87.
12. Chang KW. Clinically accurate assessment and grading of ototoxicity. Laryngoscope 2011; 121:2649-2657.
13. Campbell KC, Durrant J. Audiologic monitoring for ototoxicity. Otolaryngol Clin North Am 1993; 26:903-914.
14. Fausti SA, Henry JA, Schaffer HI, et al. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1993; 119:661-666.
15. Fausti SA, Larson VD, Noffsinger D, et al. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 1994; 15:232-239.
16. Vaughan NE, Fausti SA, Chelius S, et al. An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity. J Rehabil Res Dev 2002; 39:567-574.
17. Vasquez R, Mattucci KF. A proposed protocol for monitoring ototoxicity in patients who take cochleo- or vestibulotoxic drugs. Ear Nose Throat J 2003; 82:181-184.
18. American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy guidelines. ASHA practice policy. Published 1994. http://www.asha.org/policy. Accessed August 7, 2013.
19. Lewis MJ, DuBois SG, Fligor B, et al. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 2009; 52:387-3391.
20. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28:1788-1795.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events, Version 3.0. Published October 22, 2003. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_glossary.pdf. Accessed August 7, 2013.
22. National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.511.pdf. Published May 28, 2009. Accessed August 7, 2013.
23. Neuwelt EA, Brock P. Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 2010; 28:1630-1632.
24. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7:813-820.
25. Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26:3749-3755.
26. McKibbin T, Panetta JC, Fouladi M, et al. Clinical pharmacokinetics of amifostine and WR 1065 in pediatric patients with medulloblastoma. Clin Cancer Res 2010; 16:1049-1057.
27. De Muth JE. Basic statistics pharmaceutical statistical applications. Baton Raton FL: Chapman & Hall/CRC; 2006.
28. Low WK, Toh ST, Wee J, et al. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: A single, blinded, randomized study. J Clin Oncol 2006; 24:1904-1909.